Vertex Pharmaceuticals Inc
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age a… Read more
Vertex Pharmaceuticals Inc (VRTX) - Net Assets
Latest net assets as of December 2025: $18.67 Billion USD
Based on the latest financial reports, Vertex Pharmaceuticals Inc (VRTX) has net assets worth $18.67 Billion USD as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($25.64 Billion) and total liabilities ($6.98 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $18.67 Billion |
| % of Total Assets | 72.79% |
| Annual Growth Rate | 26.35% |
| 5-Year Change | 84.81% |
| 10-Year Change | 1294.85% |
| Growth Volatility | 184.69 |
Vertex Pharmaceuticals Inc - Net Assets Trend (1990–2025)
This chart illustrates how Vertex Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Vertex Pharmaceuticals Inc (1990–2025)
The table below shows the annual net assets of Vertex Pharmaceuticals Inc from 1990 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $18.67 Billion | +13.75% |
| 2024-12-31 | $16.41 Billion | -6.66% |
| 2023-12-31 | $17.58 Billion | +26.36% |
| 2022-12-31 | $13.91 Billion | +37.75% |
| 2021-12-31 | $10.10 Billion | +16.27% |
| 2020-12-31 | $8.69 Billion | +42.75% |
| 2019-12-31 | $6.09 Billion | +37.20% |
| 2018-12-31 | $4.44 Billion | +117.17% |
| 2017-12-31 | $2.04 Billion | +52.62% |
| 2016-12-31 | $1.34 Billion | +22.47% |
| 2015-12-31 | $1.09 Billion | -0.47% |
| 2014-12-31 | $1.10 Billion | -19.06% |
| 2013-12-31 | $1.36 Billion | +9.89% |
| 2012-12-31 | $1.23 Billion | +27.85% |
| 2011-12-31 | $965.51 Million | +91.58% |
| 2010-12-31 | $503.97 Million | -54.03% |
| 2009-12-31 | $1.10 Billion | +358.97% |
| 2008-12-31 | $238.87 Million | -11.95% |
| 2007-12-31 | $271.30 Million | -46.38% |
| 2006-12-31 | $505.94 Million | +111.53% |
| 2005-12-31 | $239.18 Million | +574.86% |
| 2004-12-31 | $35.44 Million | -81.62% |
| 2003-12-31 | $192.84 Million | -49.06% |
| 2002-12-31 | $378.58 Million | -20.36% |
| 2001-12-31 | $475.35 Million | +37.48% |
| 2000-12-31 | $345.76 Million | +65.28% |
| 1999-12-31 | $209.19 Million | -15.03% |
| 1998-12-31 | $246.20 Million | -10.80% |
| 1997-12-31 | $276.00 Million | +111.01% |
| 1996-12-31 | $130.80 Million | +53.34% |
| 1995-12-31 | $85.30 Million | -19.15% |
| 1994-12-31 | $105.50 Million | +113.13% |
| 1993-12-31 | $49.50 Million | +12.76% |
| 1992-12-31 | $43.90 Million | -15.90% |
| 1991-12-31 | $52.20 Million | +903.85% |
| 1990-12-31 | $5.20 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Vertex Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1356620000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $13.56 Billion | 72.65% |
| Common Stock | $2.50 Million | 0.01% |
| Other Comprehensive Income | $-15.90 Million | -0.09% |
| Other Components | $5.12 Billion | 27.43% |
| Total Equity | $18.67 Billion | 100.00% |
Vertex Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Vertex Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Chubb Ltd
NYSE:CB
|
$117.14 Billion |
|
TotalEnergies SE
PINK:TTFNF
|
$117.16 Billion |
|
Enbridge Inc
NYSE:ENB
|
$117.74 Billion |
|
Intesa Sanpaolo SpA PK
PINK:ISNPY
|
$117.88 Billion |
|
UBS Group AG
NYSE:UBS
|
$116.80 Billion |
|
Palo Alto Networks Inc
NASDAQ:PANW
|
$116.79 Billion |
|
McKesson Corporation
NYSE:MCK
|
$115.21 Billion |
|
Schneider Electric SE
PINK:SBGSF
|
$114.97 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Vertex Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 16,409,600,000 to 18,665,800,000, a change of 2,256,200,000 (13.7%).
- Net income of 3,953,200,000 contributed positively to equity growth.
- Share repurchases of 2,017,400,000 reduced equity.
- Other comprehensive income decreased equity by 143,700,000.
- Other factors increased equity by 464,100,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $3.95 Billion | +21.18% |
| Share Repurchases | $2.02 Billion | -10.81% |
| Other Comprehensive Income | $-143.70 Million | -0.77% |
| Other Changes | $464.10 Million | +2.49% |
| Total Change | $- | 13.75% |
Book Value vs Market Value Analysis
This analysis compares Vertex Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 6.39x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 1749.99x to 6.39x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1990-12-31 | $0.26 | $462.49 | x |
| 1991-12-31 | $3.57 | $462.49 | x |
| 1992-12-31 | $1.81 | $462.49 | x |
| 1993-12-31 | $1.98 | $462.49 | x |
| 1994-12-31 | $3.36 | $462.49 | x |
| 1995-12-31 | $2.50 | $462.49 | x |
| 1996-12-31 | $3.50 | $462.49 | x |
| 1997-12-31 | $5.69 | $462.49 | x |
| 1998-12-31 | $4.87 | $462.49 | x |
| 1999-12-31 | $4.10 | $462.49 | x |
| 2000-12-31 | $7.59 | $462.49 | x |
| 2001-12-31 | $6.38 | $462.49 | x |
| 2002-12-31 | $5.00 | $462.49 | x |
| 2003-12-31 | $2.50 | $462.49 | x |
| 2004-12-31 | $0.45 | $462.49 | x |
| 2005-12-31 | $2.68 | $462.49 | x |
| 2006-12-31 | $4.47 | $462.49 | x |
| 2007-12-31 | $2.10 | $462.49 | x |
| 2008-12-31 | $1.70 | $462.49 | x |
| 2009-12-31 | $6.33 | $462.49 | x |
| 2010-12-31 | $2.51 | $462.49 | x |
| 2011-12-31 | $3.77 | $462.49 | x |
| 2012-12-31 | $4.71 | $462.49 | x |
| 2013-12-31 | $6.03 | $462.49 | x |
| 2014-12-31 | $4.57 | $462.49 | x |
| 2015-12-31 | $4.53 | $462.49 | x |
| 2016-12-31 | $5.47 | $462.49 | x |
| 2017-12-31 | $8.07 | $462.49 | x |
| 2018-12-31 | $17.11 | $462.49 | x |
| 2019-12-31 | $23.34 | $462.49 | x |
| 2020-12-31 | $32.98 | $462.49 | x |
| 2021-12-31 | $38.86 | $462.49 | x |
| 2022-12-31 | $53.70 | $462.49 | x |
| 2023-12-31 | $67.49 | $462.49 | x |
| 2024-12-31 | $63.63 | $462.49 | x |
| 2025-12-31 | $72.35 | $462.49 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Vertex Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 21.18%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 32.94%
- • Asset Turnover: 0.47x
- • Equity Multiplier: 1.37x
- Recent ROE (21.18%) is above the historical average (-41.24%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1990 | -82.69% | -186.96% | 0.25x | 1.77x | $-4.82 Million |
| 1991 | -9.77% | -159.38% | 0.06x | 1.09x | $-10.32 Million |
| 1992 | -19.36% | -223.68% | 0.07x | 1.16x | $-12.89 Million |
| 1993 | 4.04% | 7.17% | 0.46x | 1.23x | $-2.95 Million |
| 1994 | -16.68% | -89.80% | 0.17x | 1.10x | $-28.15 Million |
| 1995 | -25.21% | -97.29% | 0.22x | 1.16x | $-30.03 Million |
| 1996 | -30.58% | -300.75% | 0.09x | 1.10x | $-53.08 Million |
| 1997 | -7.17% | -45.21% | 0.15x | 1.07x | $-47.40 Million |
| 1998 | -13.44% | -74.55% | 0.17x | 1.08x | $-57.72 Million |
| 1999 | -19.60% | -66.56% | 0.27x | 1.11x | $-61.92 Million |
| 2000 | -7.72% | -50.76% | 0.10x | 1.50x | $-91.06 Million |
| 2001 | -13.93% | -39.54% | 0.18x | 1.95x | $-113.77 Million |
| 2002 | -28.69% | -67.43% | 0.20x | 2.15x | $-146.48 Million |
| 2003 | -102.03% | -284.59% | 0.10x | 3.76x | $-216.05 Million |
| 2004 | -469.08% | -161.85% | 0.19x | 15.39x | $-169.79 Million |
| 2005 | -85.05% | -126.43% | 0.29x | 2.30x | $-227.33 Million |
| 2006 | -40.89% | -95.63% | 0.23x | 1.82x | $-257.48 Million |
| 2007 | -144.23% | -196.61% | 0.33x | 2.22x | $-418.41 Million |
| 2008 | -192.51% | -262.02% | 0.18x | 4.10x | $-483.74 Million |
| 2009 | -58.52% | -628.70% | 0.05x | 1.78x | $-751.21 Million |
| 2010 | -149.74% | -526.35% | 0.08x | 3.42x | $-805.02 Million |
| 2011 | 3.76% | 2.10% | 0.64x | 2.80x | $-49.11 Million |
| 2012 | -10.71% | -7.01% | 0.55x | 2.76x | $-206.95 Million |
| 2013 | -32.81% | -36.72% | 0.52x | 1.71x | $-580.67 Million |
| 2014 | -68.70% | -127.25% | 0.25x | 2.17x | $-846.06 Million |
| 2015 | -51.08% | -54.06% | 0.41x | 2.29x | $-667.38 Million |
| 2016 | -8.37% | -6.58% | 0.59x | 2.16x | $-245.87 Million |
| 2017 | 12.90% | 10.59% | 0.70x | 1.74x | $59.25 Million |
| 2018 | 47.28% | 68.80% | 0.49x | 1.41x | $1.65 Billion |
| 2019 | 19.34% | 28.27% | 0.50x | 1.37x | $568.29 Million |
| 2020 | 31.22% | 43.70% | 0.53x | 1.35x | $1.84 Billion |
| 2021 | 23.19% | 30.92% | 0.56x | 1.33x | $1.33 Billion |
| 2022 | 23.88% | 37.20% | 0.49x | 1.30x | $1.93 Billion |
| 2023 | 20.59% | 36.68% | 0.43x | 1.29x | $1.86 Billion |
| 2024 | -3.26% | -4.86% | 0.49x | 1.37x | $-2.18 Billion |
| 2025 | 21.18% | 32.94% | 0.47x | 1.37x | $2.09 Billion |
Industry Comparison
This section compares Vertex Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Vertex Pharmaceuticals Inc (VRTX) | $18.67 Billion | -82.69% | 0.37x | $117.09 Billion |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |